NIPH Clinical Trials Search

ARIA Registry Study

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Cerebral amyloid angiopathy or Alzheimer's disease
Date of first enrollment	22/10/2025
Target sample size	430
Countries of recruitment
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome	Not set
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	1 Individuals diagnosed with cerebral amyloid angiopathy or Alzheimer's disease 2 Individuals meeting any of the following selection criteria for each cohort group [Cohort 1: Spontaneous ARIA Group] -CAA-ri group: Individuals diagnosed with CAA-ri -Control group: Individuals diagnosed with CAA and without ARIA at the time of registration However, Cohort 1 participants must not receive anti-A-beta antibody drug administration during the study period. [Cohort 2: Anti-A-beta Antibody Drug-Related ARIA Cohort] -ARIA group: Individuals currently receiving or with a history of anti-A-beta antibody drug treatment based on guidelines for optimal use, who developed ARIA -Control group: Individuals scheduled to receive or currently receiving anti-A-beta antibody therapy based on optimal use guidelines, without ARIA at registration 3 Individuals for whom written informed consent was obtained from the subject or legal representative regarding study participation
Exclude criteria	Individuals deemed ineligible for inclusion in the study by the principal investigator or co-investigator